Compare BridgeBio Pharma Inc (BBIO) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Marsh & McLennan Companies, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Marsh & McLennan Companies, Inc. trades at $191.32 (market cap $91.05B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 5.5× BridgeBio Pharma Inc's market cap, and Marsh & McLennan Companies, Inc. pays a 2.08% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | MRSH | |
|---|---|---|
Market Cap | $16.61B | $91.05B |
Sector | Health | Financials |
52-Week High | $90.17 | $211.21 |
52-Week Low | $47.29 | $157.32 |
Enterprise Value | $18.16B | $111.73B |
Dividend Yield | — | 2.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Marsh & McLennan (MRSH) trades at $191.65, down 0.85% on the day, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.96 exceeding expectations. Revenue growth remains solid at 6% in Q2 2026, while the company maintains healthy profitability with a 14.24% net income margin. Recent acquisitions and AI investments highlight strategic growth initiatives.
The outlook for MRSH is positive, supported by earnings momentum and a consensus price target of $202.89 offering potential upside. However, margin pressure from rising expenses and soft P&C pricing present near-term risks. Institutional activity shows mixed sentiment, with some firms increasing stakes while others reduce holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
